Prothrombin complex concentrate (Beriplex P/N)

Lesley J Scott1

  • 1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 15, 2009
PubMed

Beriplex P/N, a prothrombin complex concentrate derived from pooled human plasma, contains the vitamin K-dependent coagulation factors II, VII, IX and X, and the vitamin K-dependent coagulation inhibition proteins C and S. Intravenous Beriplex P/N provided rapid and sustained normalization of elevated international normalized ratios and controlled bleeding in adult patients participating in several prospective, noncomparative clinical studies (n = 8-43), with these data supported by clinical experience during its use over more than a decade. Based on extensive clinical experience, Beriplex P/N is also effective in the treatment of congenital deficiency of any of the vitamin K-dependent coagulation factors when purified specific coagulation factor products are not available. Over a decade of clinical experience and more limited data from clinical studies have shown that intravenous infusions of Beriplex P/N were generally well tolerated in adult patients with acquired or congenital deficiencies of the vitamin K-dependent coagulation factors. To date, there have been no proven cases of viral transmission reported in any published studies.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are: